Prediction of human hepatic clearance using an in vitro plated hepatocyte clearance model

Drug Metabolism Letters

Volumn 3, Issue 4, 2009, Pages 296-307

  Chao, Piyun ^a   Barminko, Jeffrey ^b   Novik, Eric ^a   Han, Yi ^b   Maguire, Timothy ^a   Cheng, K C ^b  

^a Hurel Corporation   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CISAPRIDE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DICLOFENAC; DILTIAZEM; DISOPYRAMIDE; FELODIPINE; FENTANYL; FLUCONAZOLE; FLUOXETINE; HUMAN SERUM ALBUMIN; IMIPRAMINE; INDOMETACIN; KETOCONAZOLE; LABETALOL; LORAZEPAM; NALOXONE; NAPROXEN; NITRENDIPINE; PHENAZONE; PHENYTOIN; PINDOLOL; SILDENAFIL; TIMOLOL; UNINDEXED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER CLEARANCE; MALE; METABOLIC CLEARANCE RATE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING;

CELLS, CULTURED; HEPATOCYTES; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; SERUM ALBUMIN;

EID: 74749107890     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231209790218073     Document Type: Article

References (28)

1. Chaturvedi, P. R.; Decker, C. J.; Odinecs, A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr. Opin. Chem. Biol., 2001, 5(4), 452-463.
2. Korfmacher, W. A. Lead optimization strategies as part of a drug metabolism environment. Curr. Opin. Drug Discov. Dev., 2003, 6(4), 481-485.
3. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in. vitro metabolism data. J. Pharmacol. Exp. Ther., 1997, 283(1), 46-58.
4. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 1999, 27(11), 1350-1359.
5. Shibata, Y.; Takahashi, H.; Ishii, Y. A convenient in. vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos., 2000, 28(12), 1518-1523.
6. Blanchard, N.; Richert, L.; Notter, B.; Delobel, F.; David, P.; Coas-solo, P.; Lave, T. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur. J. Pharm. Sci., 2004, 23(2), 189-199.
7. Berezhkovskiy, L. M.; Khojasteh, S. C.; Halladay, J. S.; Hop, C. E. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. J. Pharm. Sci., 2009, 98(6), 1922-1927.
8. Lu, C.; Li, P.; Gallegos, R.; Uttamsingh, V.; Xia, C. Q.; Miwa, G. T.; Balani, S. K.; Gan, L. S. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab. Dispos., 2006, 34(9), 1600-1605.
9. Lau, Y. Y.; Sapidou, E.; Cui, X.; White, R. E.; Cheng, K.-C. Development of a Novel in Vitro Model to Predict Hepatic Clearance Using Fresh, Cryopreserved, and Sandwich-Cultured Hepatocytes. Drug Metab. Dispos., 2002, 30(12), 1446-1454.
10. Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos., 2003, 31(5), 580-588.
11. Pang, K. S.; Rowland, M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm., 1977, 5(6), 625-653.
12. Shibata, Y.; Takahashi, H.; Chiba, M.; Ishii, Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos., 2002, 30(8), 892-896.
13. Stringer, R.; Nicklin, P. L.; Houston, J. B. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica, 2008, 38(10), 1313-1329.
14. Lau, Y. Y.; Wu, C. Y.; Okochi, H.; Benet, L. Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther., 2004, 308(3), 1040-1045.
15. Li, C.; Liu, T.; Cui, X.; Uss, A. S.; Cheng, K. C. Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J. Biomol. Screen, 2007, 12(8), 1084-1091.
16. Chu, I.; Nomeir, A. A. Utility of mass spectrometry for in vitro ADME assays. Curr. Drug Metab., 2006, 7(5), 467-477.
17. Brown, H. S.; Griffin, M.; Houston, J. B. Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance. Drug Metab. Dispos., 2007, 35(2), 293-301.
18. Berezhkovskiy, L. M. Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal. J. Pharmacokinet. Pharmacodyn., 2006, 33(5), 595-608.
19. Berezhkovskiy, L. M. On the calculation of the concentration dependence of drug binding to plasma proteins with multiple binding sites of different affinities: determination of the possible variation of the unbound drug fraction and calculation of the number of binding sites of the protein. J. Pharm. Sci., 2007, 96(2), 249-257.
20. Li, C.; Nair, L.; Liu, T.; Li, F.; Pichardo, J.; Agrawal, S.; Chase, R.; Tong, X.; Uss, A. S.; Bogen, S.; Njoroge, F. G.; Morrison, R. A.; Cheng, K. C. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem. Pharmacol., 2008, 75(5), 1186-1197.
21. Riley, R. J.; McGinnity, D. F.; Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from in. vitro intrinsic clearance data in hepatocytes and microsomes. Drug. Metab. Dispos., 2005, 33(9), 1304-1311.
22. Naritomi, Y.; Terashita, S.; Kimura, S.; Suzuki, A.; Kagayama, A.; Sugiyama, Y. Prediction of Human Hepatic Clearance from in. Vivo Animal Experiments and in Vitro Metabolic Studies with Liver Microsomes from Animals and Humans. Drug Metab. Dispos., 2001, 29(10), 1316-1324.
23. Ito, K.; Houston, J. B. Comparison of the use of liver models for predicting drug clearance using in. vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res., 2004, 21(5), 785-792.
24. Yang, J.; Jamei, M.; Yeo, K. R.; Rostami-Hodjegan, A.; Tucker, G. T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos., 2007, 35(3), 501-502.
25. Brunton, L. L.; Lazo, J. S.; Parker, K. L., Goodman. &. Gilman's. The Pharmacological Basis of Therapeutics, 11th ed.; McGRAWHILL, Medical Publishing Division: New York, 2006.
26. Ali, H. A.; el-Yazigi, A.; Sieck, J. O.; Dossing, M.; Saour, J.; Raines, D. A.; Ernst, P. Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians. Hum. Exp. Toxicol., 1994, 13(10), 658-662.
27. Ferron, G. M.; Paul, J. C.; Fruncillo, R. J.; Martin, P. T.; Yacoub, L.; Mayer, P. R. Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J. Clin. Pharmacol., 1999, 39(9), 945-950.
28. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res., 2008, 36(Database issue), D901-906.